8x8 Inc vs Globus Medical Inc. Class A Common Stock — how do they compare? 8x8 Inc trades at $2.02 (market cap $296.09M), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 34.6× 8x8 Inc's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, 8x8 Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 8x8 Inc for 16 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| EGHT | GMED | |
|---|---|---|
Market Cap | $296.09M | $10.25B |
Volume | 1,073,599 | 1,108,124 |
Sector | Technology | Health |
52-Week High | $2.76 | $96.82 |
52-Week Low | $1.59 | $58.33 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $563.02M | $9.76B |
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.05, up 0.49% today, with a mixed technical picture showing bullish oscillators but bearish moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and projected profitability in 2026. Recent news highlights cost-saving customer implementations and AI platform growth, while analyst consensus remains divided with a $19.77 price target representing significant upside potential from current levels.
The stock presents a high-risk, high-reward opportunity with substantial upside if the company achieves projected profitability, though current negative earnings and high debt levels pose execution risks. Institutional interest is growing with recent position increases, but the stock requires careful monitoring of Q3 2026 earnings results and debt management progress.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →